Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns

Oct 16 2018

• By Joseph Haas

Economics graph

Related Content

J&J Supports ‘Spirit’ Of DTC Pricing Transparency, But Prefers PhRMA’s Voluntary Approach

Oct 16 2018

J&J Immunology Growth Now Hinges On Stelara, Tremfya After RA Setback

Oct 17 2017

PTAB Clears Path For Earlier Generic Zytiga Launch

Jan 19 2018

At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise

Apr 17 2018

J&J Well Positioned For US Drug Pricing Changes Regardless Of Timing Or Form, Duato Says

Sep 13 2018

As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint

Jul 17 2018

Related Companies

Johnson & Johnson

Additional Topics

Sales & Earnings Business Strategies Commercial Companies BioPharmaceutical Cancer

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window